| DON'T BUY | 16.910 | Jeff Parent | This one is definitely in the bear phase. You have to go back to 2005 to see any sort of support, $15.50. Still has about 10% that it could drop. Volume is sporadic and he is inclined to see it drop to $15. Wait for it to confirm that it is in an uptrend. | 2008-02-20 | |
| DON'T BUY | 19.490 | Jeff Parent | His company has a Short position in this. Stock has tested support 3 times and has broken through. The chart shows an indicator giving a lot of potential of the stock moving down. Could be $16-$17 on the downside but would have trouble moving back up above $20. | 2007-12-14 | |
| HOLD | 21.430 | Robert Floyd | Just reported and the numbers were quite encouraging. Looks like some of the restructuring is starting to take hold. | 2007-09-06 | |
| SELL | 21.050 | James Cole, BA, CFA | Used to hold it, but it didn't perform as well as some of it's peers. Only holds in some minor funds. | 2007-06-12 | |
| SELL | 21.870 | Michael Sprung | Sold off a number of their assets so doesn't have as much lab business now. It is more of a scientific research company and much more volatile. Fully valued now. | 2007-04-11 | |
| SELL | 19.590 | David Driscoll | Had a huge turnover in the last 8 years, where the pharmacy side of the business didn’t do well and the medical lab side was under scrutiny. Have a new CFO and CEO who will have to try and stop the bleeding. | 2006-10-20 | |
| HOLD | 20.500 | David Burrows | Market weakness is having an impact on this stock. It is going through a restructuring which could create some positive things going forward. | 2006-06-15 | |
| DON'T BUY | 20.200 | Brian Acker, CA | As a model price of $23.24 which is a 16% differential. Thinks the top on this is $21.55. More exciting things out there. | 2005-12-21 | |
| HOLD | 19.300 | David Taylor, MBA, CFA | Has a lot of interesting assets that are cheap. Thinks new management now has a mandate to shake things up. Thinks there will be some spin offs. | 2005-08-29 | |
| HOLD | 19.700 | Ron Meisels | Has been base building since 2001. All you want now is for the stock to hit around $20 which would be a signal for the next leg. If the stock drops below $17, Sell. | 2005-07-07 | |
| DON'T BUY | 18.570 | David Driscoll | They have management changeover, so the juries out. Until you see what the new CEO is going to do and what direction the company is going to move, the stock won't do much. | 2005-06-28 | |
| HOLD | 18.310 | Ross Healey | His Fair Market Value is up around $27/28 and the stock looks like it is basing at about 1.5 X book and has been for some little while. | 2005-06-16 | |
| DON'T BUY | 16.640 | John Zechner | The key multiples are trading below average and charts don't look too bad, so there may not be much downside. On the other hand, there's nothing really clicking there to generate any decent earnings growth. | 2005-02-14 | |
| WATCH | 16.540 | David Taylor, MBA, CFA | On their watch list. Has been a real dog and shareholders are unhappy. Has been very complicated to analyze because it has so many different businesses. | 2005-02-02 | |
| HOLD | 15.680 | Danny Tomka | Very interesting at this level. Break up value would be towards $19. Management has been questionable in terms of materializing value for shareholders. Has been a chronic underperformer on an operating basis and stock. Could be a trust. | 2005-01-26 | |
| DON'T BUY | 17.070 | Gavin Graham | Sold his holdings 18 months 2 years ago. There was always something that wasn't working. There are nice things in there and if they ever got it sorted out, it would be a good company and a fairly profitable investment. Just reported more disappointing numbers. | 2004-12-30 | |
| DON'T BUY | 17.400 | Laura Wallace | Just reported a disappointing quarter. Wasn't able to mitigate the impact of the 20% fee cut that B.C. put through. Theoretically this should be a great stock as the demographics are very positive. At current multiples it is not an attractive investment. | 2004-12-23 | |
| DON'T BUY | 19.010 | Robert McWhirter | Has historically struggled in spite of a variety of different managers being on the scene. Ranks neutral at 347 of the data base model. Year over year sales is bland at 4% although earnings is up 15%. | 2004-12-09 | |
| WAIT | 19.660 | James Cole, BA, CFA | Have not invested their free cash flow wisely. Have been making changes to get more focus on capital employed. Wait to see who the new CEO will be and their focus. | 2004-10-18 | |
| BUY | 19.230 | Bill Carrigan | Has been weak, but feels it is fine now. This should be held with a basket of similar health related stocks. | 2004-09-14 | |
| DON'T BUY | 18.850 | David Baskin | Has been a disappointment over the last 2/3 years. Prefers US medical services. | 2004-09-09 | |
| HOLD | 20.600 | James Cole, BA, CFA | Have not been satisfied with the stock. Throws off a lot of free cash flow which has not been invested wisely. Starting to focus on return of capital. Has had some good management changes. | 2004-06-30 | |
| HOLD | 20.100 | Michael Smedley | Steady. Highly skilled operation. | 2004-06-16 | |
| BUY | 20.150 | Blair Wilson | Very favourable to this stock. Have a sector out-perform on it. One of the top 3 Canadian names. Disappointing last quarter is not likely to be repeated. Buy on this weakness. | 2004-06-15 | |
| BUY | 21.730 | Larry Berman CFA, CMT, CTA | Has significant overhead resistance at $25 and strong support at $18. Expects it to move up to the $25 area. | 2004-05-31 | |
| DON'T BUY | 22.300 | Ross Healey | Hasn't done anything for few years, and possibly won't. Fair market value is a little higher than its current price. | 2004-04-29 | |
| PAST TOP PICK | 22.000 | Bill Carrigan | (A top pick Oct 4/03. Up 10%.) Still likes. | 2004-04-28 | |
| BUY | 21.950 | Jonathen Wellum, B. Comm, B. Sc | Has been disappointed with execution over the last few years. Feels they are aggressively redressing some of those concerns. Feels the stock is undervalued. | 2004-04-02 | |
| HOLD | 22.050 | Michael Sprung | Reduced exposure. May do something great in the future. Own very little | 2004-03-30 | |
| DON'T BUY | 22.000 | Ian Ainsworth | A good company but they have trouble showing real growth and profitability. Their proteomics seems to be faltering. There is pressure and they may have to restructure. | 2004-03-26 | |
| DON'T BUY | 21.060 | Ted Macklin | This stock has stalled and is frustrating. Can't see them getting 15% growth as they predicted. | 2004-02-26 | |
| HOLD | 19.900 | Pierre Bernard | Had been a great fan of the Company until last year. Started to lose interest when the CFO left. Expensive. | 2004-01-13 | |
| DON'T BUY | 20.150 | John Zechner | A little bit of dead money right now. All their areas seem to be having troubles. Doesn't see big earnings growth. | 2004-01-12 | |
| WEAK BUY | 19.980 | Ray Steele | Relatively solid company. Good cash flow from parts of their business. | 2003-12-31 | |
| DON'T BUY | 19.010 | Ted Macklin | A frustrating stock. A good company. Needs some kind of catalyst. | 2003-12-16 | |
| DON'T BUY | 18.220 | Ron Meisels | Building a base and has not broken out above the trend line yet. If you own it, put a stop loss on it around $17. | 2003-11-26 | |
| DON'T BUY | 19.090 | John Zechner | Not much downside risk, but doesn’t expect it to move much. New management is trying to streamline things. No real spark plugs in the company. Dead money. | 2003-11-13 | |
| BUY on WEAKNESS | 19.000 | Peter Brieger | Feels it's in an interesting turnaround and they are starting to look at. Would consider at $17.50/18. | 2003-11-12 | |
| DON'T BUY | 19.800 | Laura Wallace | Has not been transparent to investors with respect to what's going on in its business and its accounting. A “Show Me” stock. | 2003-10-31 | |
| WAIT | 19.940 | Ted Macklin | Proteomics is executing their well in a difficult environment. The US lab business has not done well and expects they will sell it. Still frustrated that there are no concrete numbers that he can't hold them accountable to. Have to see more visibility | 2003-10-30 | |
| TOP PICK | 19.990 | Bill Carrigan | A bit of a laggard. Long-term chart indicates that it did not take out its low this year and starting to break out over its trend line. Volume is starting to come in. | 2003-10-14 | |
| BUY | 18.960 | Ray Steele | Has been languishing. Now is quite a good entry point. Relatively safe. | 2003-10-03 | |
| HOLD | 18.680 | Ted Macklin | A very good company. Expect they will go through some restructuring. Need to see some form of catalyst to improve the earnings growth outlook and to exit some of their businesses that are not profitable. | 2003-09-23 | |
| BUY | 19.220 | Peter Arender, CFA | Not sure why they are lagging. | 2003-09-03 | |
| DON'T BUY | 19.050 | David Baskin | Seems to be highly regulated by provincial ministries of health.Afraid that this could cut into profits. | 2003-08-19 | |
| BUY on WEAKNESS | 19.200 | Bruce Campbell | A one-year target of $22/23.Would buy around the $16/17 mark. | 2003-08-18 | |
| HOLD | 17.430 | Ian Ainsworth | Can't seem to get all the engines firing at the same time. Sell on any rally. | 2003-07-24 | |
| DON'T BUY | 17.630 | David Burrows | Has been a pretty weak performer in a strong sector. | 2003-07-15 | |
| DON'T BUY | 17.680 | Brian Acker, CA | Have a model price of $21. Fully valued. | 2003-07-14 | |
| WAIT | 18.500 | Bill Carrigan | If it breaks through the 2 lows of around $18, it will really drop. | 2003-07-02 | |
| DON'T BUY | 18.800 | Richard Stone | Has an interesting basket of venture capital businesses which have created some problems. Will take a while for the stock to settle down. Be patient. | 2003-06-20 | |
| DON'T BUY | 18.500 | Peter Brieger | Performance has been poor. Starting to look at this stock now. Still somewhat pricey. | 2003-06-16 | |
| BUY | 18.750 | Michael Sprung | Price looks good. Well diversified and well managed. | 2003-06-12 | |
| BUY on WEAKNESS | 18.310 | Mark Jackson, CFA | Always looked expensive. Would be a buyer in the $15 range. | 2003-06-10 | |
| BUY | 18.340 | Brendan Caldwell | A way to participate in the Cdn biotechs. Not heavily traded. | 2003-06-09 | |
| WEAK BUY | 20.080 | Richard Stone | Has been disappointing. Has some overhang (Hemasol, Proteonomics, venture capital stuff) before it can really get going. | 2003-06-03 | |
| TOP PICK | 20.100 | Gavin Graham | Had one or two disappointments however, but some divisions are doing very well. Research equipment is selling even in a down market. | 2003-05-22 | |
| DON'T BUY | 19.550 | David Burrows | Doesn't seem to be participating with the market. | 2003-05-13 | |
| BUY | 20.000 | Brian Acker, CA | Worth $22/25. Doesn't expect anything big. | 2003-05-06 | |
| BUY on WEAKNESS | 19.120 | Lou Schizas | The trend on this stock has been down. Pharma Services division is not holding up. Also, a joint venture in the US didn't do well. Treat as a trading stock. | 2003-05-02 | |
| BUY | 19.230 | Gavin Graham | Trades in a tight range. Drug companies are in a bit of a squeeze. Has one or two misses in getting value out of some of their assets. A quality stock. | 2003-04-29 | |
| BUY | 18.750 | Robert Floyd | Feels the pharma and scienx divisions are going to be the two drivers for it. Should have modest earnings going forward. | 2003-04-25 | |
| BUY | 18.450 | John Sinkins, CFA | Likes this sector and should grow reasonably well. | 2003-03-31 | |
| BUY | 18.580 | Andrew McCreath | Have yet to hit a home run. A potential of base profit growth on their lab assets because of Ontario government. Reasonable investment. | 2003-03-28 | |
| BUY | 18.600 | Michael Sprung | Has dropped because of market sell off of Hemasol and Sciex division. At a good price. | 2003-03-20 | |
| BUY | 18.600 | Mike Weir | Heamasol was a problem. Good price. Growth prospects. | 2003-03-20 | |
| BUY | 19.200 | Ted Macklin | The stock got hit because one of their distributors gave a profit warning. Has been oversold and is a good price. | 2003-03-20 | |
| DON'T BUY | 18.590 | Ross Healey | Has dropped through the $20 technical support level. Would look at it at $15. | 2003-03-19 | |
| BUY | 20.300 | David Burrows | Interesting component parts. Health care in the US is rallying. | 2003-03-17 | |
| PAST TOP PICK | 21.600 | Richard Stone | (Was a top pick on Nov 5. Down 3.8%.) Still likes. | 2003-01-30 | |
| PAST TOP PICK | 21.860 | Pierre Bernard | (Was a top pick on Oct 29. No change.) Still likes. | 2003-01-20 | |
| WAIT | 21.860 | Brendan Kyne | Has concerns that the CFO has left on such short notice with no one ready to step in. | 2003-01-20 | |
| DON'T BUY | 22.000 | Jeff Morrison | A defensive type of holding. Doesn't expect much upside. | 2002-12-27 | |
| BUY | 21.440 | Ted Macklin | Strong cash flow from their labs. Starting to fire on all cylinders now. Proteomics are looking better. | 2002-12-23 | |
| DON'T BUY | 22.580 | Ross Healey | Fair market value is $27/28. Stock is in a trading range of $20/25. | 2002-12-12 | |
| WEAK BUY | 22.400 | Bruce Campbell | Earnings have flattened out. | 2002-11-07 | |
| TOP PICK | 22.700 | Richard Stone | (Was a top pick on Oct 10. Down 7.4%. ) Good production. Well focused management. | 2002-11-05 | |
| TOP PICK | 22.600 | Pierre Bernard | Good portfolio of health related activities. | 2002-10-29 | |
| BUY | 22.930 | David Burrows | Their lab business could be sold at a premium. Keep a stop loss on it. | 2002-10-28 | |
| TOP PICK | 21.020 | Richard Stone | (Was a top pick on July 2. Down 12.5%) | 2002-10-10 | |
| HOLD | 23.700 | Michael Sprung | Profitable. Well managed. | 2002-09-10 | |
| TOP PICK | 24.000 | Larry Berman CFA, CMT, CTA | Buy in low $20's and sell at $25. | 2002-09-03 | |
| BUY on WEAKNESS | 21.400 | Brian Acker, CA | Their quantum model price is $22. | 2002-07-25 | |
| TOP PICK | 19.800 | Richard Stone | Well run. Good revenues. Likes their proteomics side. | 2002-07-23 | |
| TOP PICK | 23.660 | Richard Stone | (Was a top pick on May 30. Up 7%) Great last quarter. Margins are improving. Should have great growth over next few years. | 2002-07-02 | |
| BUY | 24.200 | Ted Macklin | Strong cash flow. Long term on proteomics looks good. | 2002-06-28 | |
| BUY | 24.100 | Ted Macklin | Likes their diagnostic reader and isotope division. Has the proteomics area which is using up cash. Would like to see an IPO issued. | 2002-06-05 | |
| TOP PICK | 22.550 | Richard Stone | (Was a top pick on Feb 18. Up 6%) Perfect mix. 1.6/1.7 billion in revenue. Protonomics has been a drag. All the pieces are now starting to fit together. Fully valued now, but would like to buy on any weakness. | 2002-05-30 | |
| DON'T BUY | 22.500 | Brian Acker, CA | Their model price is $21/21.50. Doesn't see much upside. | 2002-05-28 | |
| DON'T BUY | 21.350 | Bob Boaz | Good company, but fully valued. Good management. HOLD if you own. | 2002-05-08 | |
| TOP PICK | 21.490 | Richard Stone | Has a good basket of biotechs opportunities. Historically grows its revenue base by over 15% over a 5 year period. | 2002-05-08 | |
| TOP PICK | 20.990 | Pierre Bernard | (Was a top pick on Jan 22 no change) Still likes. Well diversified. | 2002-05-07 | |
| DON'T BUY | 21.360 | Ross Healey | At FMV. Needs more earnings. | 2002-04-25 | |
| BUY | 21.980 | Mike Weir | Has some good business which are now in better shape. | 2002-04-16 | |
| BUY on WEAKNESS | 22.500 | Glenn Paradis, BA, CFA | A good company. Would buy, but only on some weakness. | 2002-04-01 | |
| BUY | 22.980 | Rob Callander | An expensive stock, but a good long term hold. | 2002-03-20 | |
| PAST TOP PICK | 20.950 | Richard Stone | (Was a top pick on Nov 15 up 7%)Still likes. Good revenues. | 2002-02-28 | |
| PAST TOP PICK | 20.650 | Michael Smedley | Still likes. | 2002-02-21 | |
| TOP PICK | 21.000 | Richard Stone | A well positioned business. Good core holding. | 2002-02-18 | |
| TOP PICK | 21.040 | Michael Sprung | Good assets/products. Good management. | 2002-02-11 | |
Experts that have talked about MDS Inc
Rss Top Picks Feed
